Article Text

other Versions

Drug-eluting balloon for instent restenosis: the response
  1. Rahul Bahl1,
  2. Andreas Indermuehle2,
  3. Georg M Froehlich1,
  4. Alexandra J Lansky3,
  5. Guido Knapp4,
  6. Adam Timmis5,
  7. Pascal Meier1,3
  1. 1Department of Cardiology, University College London Hospitals, London, UK
  2. 2Department of Cardiology, Hospital Biel, Biel, Switzerland
  3. 3Division of Cardiology, Yale Medical School, New Haven, Connecticut, USA
  4. 4Department of Statistics, TU University of Dortmund, Dortmund, Germany
  5. 5NIHR Biomedical Research Unit, Barts and the London School of Medicine and Dentistry, London Chest Hospital, London, UK
  1. Correspondence to Dr Pascal Meier, Division of Cardiology, Yale Medical School, New Haven, CT, USA CT06510; Department of Cardiology, University College London UCL Hospitals, London W1G 8PH, UK; pascalmeier74{at}

Statistics from

The Authors’ reply We thank Chen et al1 for their feedback on our paper2 and we fully agree with most of their comments. Instent restenosis continues to be a problem even though the risk has been massively reduced by drug coating of stents.3 A significant proportion of patients had contraindications for drug-eluting stents (DES).

Regarding the short-term and long-term follow-up data available for the PACCOCATH trial, we generally …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles